Jacek Capala

List of Publications by Year
in descending order

50	1,954	218677	243625
papers	citations	26 h-index	44 g-index

54	54	54	2887
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Tumor Heterogeneity Research and Innovation in Biologically Based Radiation Therapy From the National Cancer Institute Radiation Research Program Portfolio. Journal of Clinical Oncology, 2022, 40, 1861-1869.	1.6	1
2	Overview of the First NRG Oncologyâ€“National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy. Journal of Nuclear Medicine, 2021, 62, 1133-1139.	5.0	5
3	A New Generation of â€œMagic Bulletsâ€•for Molecular Targeting of Cancer. Clinical Cancer Research, 2021, 27, 377-379.	7.0	2
4	Current Status of Radiopharmaceutical Therapy. International Journal of Radiation Oncology Biology Physics, 2021, 109, 891-901.	0.8	44
5	Toward Individualized Voxel-Level Dosimetry for Radiopharmaceutical Therapy. International Journal of Radiation Oncology Biology Physics, 2021, 109, 902-904.	0.8	5
6	Moving Forward in the Next Decade: Radiation Oncology Sciences for Patient-Centered Cancer Care. JNCI Cancer Spectrum, 2021, 5, pkab046.	2.9	6
7	National Cancer Institute support for targeted alpha-emitter therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 64-72.	6.4	3
8	Phase 0 Radiopharmaceuticalâ€“Agent Clinical Development. Frontiers in Oncology, 2020, 10, 1310.	2.8	8
9	Advancing Targeted Radionuclide Therapy Through the National Cancer Instituteâ€™s Small Business Innovation Research Pathway. Journal of Nuclear Medicine, 2019, 60, 41-49.	5.0	10
10	Targeted Drug Delivery and Image-Guided Therapy of Heterogeneous Ovarian Cancer Using HER2-Targeted Theranostic Nanoparticles. Theranostics, 2019, 9, 778-795.	10.0	82
11	Accurate, Precision Radiation Medicine: A Meta-Strategy for Impacting Cancer Care, Global Health, and Nuclear Policy and Mitigating Radiation Injury From Necessary Medical Use, Space Exploration, and Potential Terrorism. International Journal of Radiation Oncology Biology Physics, 2018, 101, 250-253.	0.8	13
12	Response to â€œComment on â€˜Medical use of all high activity sources should be eliminated for security concernsâ€™â€‰â€•[Med. Phys. 42, 6773â€“6775 (2015)]. Medical Physics, 2016, 43, 4461-4461.	3.0	0
13	Preclinical Data on Efficacy of 10 Drug-Radiation Combinations: Evaluations, Concerns, and Recommendations. Translational Oncology, 2016, 9, 46-56.	3.7	48
14	Targeted Radionuclide Therapy: Practical Applications and Future Prospects. Biomarkers in Cancer, 2016, 8s2, BIC.S31804.	3.6	42
15	Overview of the American Society for Radiation Oncologyâ€“National Institutes of Healthâ€“American Association of Physicists in Medicine Workshop 2015: Exploring Opportunities for Radiation Oncology in the Era of Big Data. International Journal of Radiation Oncology Biology Physics, 2016, 95, 873-879.	0.8	27
16	How Will Big Data Improve Clinical and Basic Research in Radiation Therapy?. International Journal of Radiation Oncology Biology Physics, 2016, 95, 895-904.	0.8	25
17	Imaging and Data Acquisition in Clinical Trials for Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 94, 404-411.	0.8	17
18	Medical use of all high activity sources should be eliminated for security concerns. Medical Physics, 2015, 42, 6773-6775.	3.0	4

#	Article	IF	Citations
19	In Vivo Assessment of HER2 Receptor Density in HER2-positive Tumors by Near-infrared Imaging, Using Repeated Injections of the Fluorescent Probe. TCRT Express, 2014, 13, 427-34.	1.5	4
20	Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. Oncotarget, 2014, 5, 5934-5949.	1.8	59
21	ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. Oncotarget, 2014, 5, 6633-6646.	1.8	66
22	Polylactide-Based Paclitaxel-Loaded Nanoparticles Fabricated by Dispersion Polymerization: Characterization, Evaluation in Cancer Cell Lines, and Preliminary Biodistribution Studies. Journal of Pharmaceutical Sciences, 2014, 103, 2546-2555.	3.3	21
23	PET of HER2-Positive Pulmonary Metastases with ¹⁸F-Z_{HER2:342} Affibody in a Murine Model of Breast Cancer: Comparison with ¹⁸F-FDG. Journal of Nuclear Medicine, 2012, 53, 939-946.	5.0	29
24	In Vivo Method to Monitor Changes in HER2 Expression Using Near-Infrared Fluorescence Imaging. Molecular Imaging, 2012, 11, 7290.2011.00038.	1.4	13
25	In Vivo Fluorescence Lifetime Imaging Monitors Binding of Specific Probes to Cancer Biomarkers. PLoS ONE, 2012, 7, e31881.	2.5	33
26	Affibody-DyLight Conjugates for In Vivo Assessment of HER2 Expression by Near-Infrared Optical Imaging. PLoS ONE, 2012, 7, e41016.	2.5	19
27	The role of nuclear medicine in modern therapy of cancer. Tumor Biology, 2012, 33, 629-640.	1.8	32
28	In vivo method to monitor changes in HER2 expression using near-infrared fluorescence imaging. Molecular Imaging, 2012, 11, 177-86.	1.4	9
29	PET/CT Imaging and Radioimmunotherapy of Prostate Cancer. Seminars in Nuclear Medicine, 2011, 41, 29-44.	4.6	84
30	Hyperthermia-triggered intracellular delivery of anticancer agent to HER2+ cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2+ affisomes). Journal of Controlled Release, 2011, 153, 187-194.	9.9	75
31	Sarcosine induces increase in HER2/neu expression in androgen-dependent prostate cancer cells. Molecular Biology Reports, 2011, 38, 4237-4243.	2.3	18
32	68Ga-DOTA-Affibody molecule for in vivo assessment of HER2/neu expression with PET. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1967-1976.	6.4	48
33	HER2-Affitoxin: A Potent Therapeutic Agent for the Treatment of HER2-Overexpressing Tumors. Clinical Cancer Research, 2011, 17, 5071-5081.	7.0	46
34	Using In-Vivo Fluorescence Imaging in Personalized Cancer Diagnostics and Therapy, an Image and Treat Paradigm. Technology in Cancer Research and Treatment, 2011, 10, 549-560.	1.9	31
35	Molecular imaging of HER2-positive breast cancer: a step toward an individualized â€˜image and treatâ€™ strategy. Current Opinion in Oncology, 2010, 22, 559-566.	2.4	95
36	â€˜Image and treatâ€™: an individualized approach to urological tumors. Current Opinion in Oncology, 2010, 22, 274-280.	2.4	33

#	Article	IF	Citations
37	Quantitative Analysis of HER2 Receptor Expression In Vivo by Near-Infrared Optical Imaging. Molecular Imaging, 2010, 9, 7290.2010.00018.	1.4	29
38	HER2â€•and EGFRâ€Specific Affiprobes: Novel Recombinant Optical Probes for Cell Imaging. ChemBioChem, 2010, 11, 345-350.	2.6	35
39	Quantitative analysis of Her2 receptor expression in vivo by near-infrared optical imaging. Molecular Imaging, 2010, 9, 192-200.	1.4	22
40	Prostate specific membrane antigen- a target for imaging and therapy with radionuclides. Discovery Medicine, 2010, 9, 55-61.	0.5	91
41	Changes inHER2Expression in Breast Cancer Xenografts After Therapy Can Be Quantified Using PET and¹⁸F-Labeled Affibody Molecules. Journal of Nuclear Medicine, 2009, 50, 1131-1139.	5.0	96
42	Affitoxinâ€"A Novel Recombinant, HER2-specific, Anticancer Agent for Targeted Therapy of HER2-positive Tumors. Journal of Immunotherapy, 2009, 32, 817-825.	2.4	63
43	Positron emission tomography/computed tomography and radioimmunotherapy of prostate cancer. Current Opinion in Oncology, 2009, 21, 469-474.	2.4	26
44	[18F]FBEM-ZHER2:342-Affibody moleculeâ€"a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1008-1018.	6.4	137
45	Radiolabeling of HER2-specific AffibodyÂ® molecule with F-18. Journal of Fluorine Chemistry, 2008, 129, 799-806.	1.7	37
46	HER2-Specific Affibody-Conjugated Thermosensitive Liposomes (Affisomes) for Improved Delivery of Anticancer Agents. Journal of Liposome Research, 2008, 18, 293-307.	3.3	95
47	Affibody Molecules for In vivo Characterization of HER2-Positive Tumors by Near-Infrared Imaging. Clinical Cancer Research, 2008, 14, 3840-3849.	7.0	164
48	Accuracy of 3D volumetric image registration based on CT, MR and PET/CT phantom experiments. Journal of Applied Clinical Medical Physics, 2008, 9, 17-36.	1.9	25
49	Registering Molecular Imaging Information into Anatomic Images with Improved Spatial Accuracy. , 2007, , .		3
50	Effects of131I-EGF on cultured human glioma cells. Journal of Neuro-Oncology, 1990, 9, 201-210.	2.9	23